Sichuan Kelun-Biotech Biopharmaceutical Co Ltd, a holding subsidiary of Kelun Pharmaceutical (SZ:002422), announced on Monday that the new drug application (NDA) for its small molecule rearranged during transfection (RET) kinase inhibitor A400 (EP0031) has been accepted for review by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA).
The product is intended for the treatment of adult patients with RET-fusion positive locally advanced, or metastatic non-small cell lung cancer (NSCLC).
This acceptance for review is based on positive results from the two pivotal Phase 2 cohorts of the KL400-I/II-01 study for both 1L and 2L+ advanced RET-fusion positive NSCLC.
Sichuan Kelun-Biotech Biopharmaceutical NDA for A400 accepted for review in China
Akeso showcasing late-breaking abstract from ivonescimab study at ESMO
TransMedics and Mercedes-Benz to launch dedicated organ transport network in Italy
N4 Pharma advances RNA delivery breakthrough with SRI collaboration
CorestemChemon presents Neuronata-R Phase 3 results at PACTALS 2025
AstraZeneca's Fasenra misses primary endpoint in Phase III COPD trial
GSK commits USD30bn to US R&D and manufacturing expansion
Hydrosome Labs announces promising fermentation breakthrough with ultrafine bubbles
Amgen and Kyowa Kirin release rocatinlimab study results in atopic dermatitis